The CDMO with a capital D

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Harry Christiaens, CEO at Ardena. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Harry, covering: How a regulatory change led a small consultancy down the path of becoming one of Europe’s most respected mid-sized CDMOs The easy-theory of an M&A buy-and-build strategy, versus the challenging practical realities after acquiring and integrating five businesses Key considerations and questions you should ask before selecting a private equity partner The role of nano-technology in producing nanomedicines for effective targeting of disease…but also the challenges of dealing with this enabling platform Why there is cause for optimization for CDMOs when looking at the robust R&D funding environment and forecasted outsourcing growth Harry has significant leadership experience with 20+ years in the pharma and biotech industry. He successfully transformed Pharmavize, a regulatory consultancy company into a leading CDMO, establishing a GMP team and infrastructure from scratch. Since 2015, he led the acquisitions and integration of five companies providing highly complementary services. He successfully integrated the service offering of the acquired companies onto one platform, creating the Ardena brand. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.